“…According to the phase 2 study of moderate hypofractionated IMRT (70 Gy in 28 fractions), the biochemical failure-free survival rate was 97.4% at 5 years. 20 Similarly, according to a retrospective analysis, which investigated the impact of prostate position-based IGRT among intermediate-risk PCa treated with IMRT (76 Gy in 38 fractions), the biochemical failure-free rate was 94.9% at 10 years. 21 On the other hand, for the high-risk PCa population, there is still room for improvement regarding tumor control by local dose-escalation.…”